Introduction: About one third of patients affected with thyroid cancer present with recurrent disease. Unresectability, advanced disease and radioiodine refractoriness are considered poor prognostic factors. Treatment with small molecules inhibiting molecular signaling can be considered for patients with progressive disease, when other therapeutic strategies cannot be applied. Lenvatinib is a tyrosine kinase inhibitor targeting multiple molecular factors involved in angiogenesis and tumor progression. Preclinical studies have demonstrated the utility of lenvatinib as a targeted therapy for different tumors, including both differentiated and anaplastic thyroid cancer. Areas covered: The authors provide an overview of the preclinical development of lenvatinib in the treatment of thyroid cancer and review its clinical application. They also provide their expert opinion on its development. Expert opinion: Preclinical studies have helped in the understanding of the mechanisms of thyroid carcinogenesis and in the development of a targeted therapy. These findings have represented the rationale for the use of lenvatinib in clinical trials, which have confirmed its utility but yet failed to prove a clear benefit in overall survival. The decision to start a systemic treatment with lenvatinib must be personalized for each patient evaluating the risk/benefits ratio. Treatment emergent adverse events must be considered and reasonably managed by a multidisciplinary approach.

Paragliola, R. M., Corsello, A., Del Gatto, V., Papi, G., Pontecorvi, A., Corsello, S. M., Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application, <<EXPERT OPINION ON DRUG DISCOVERY>>, 2020; 15 (1): 11-26. [doi:10.1080/17460441.2020.1674280] [http://hdl.handle.net/10807/153190]

Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application

Paragliola, R. M.
Writing – Original Draft Preparation
;
Corsello, A.
Writing – Original Draft Preparation
;
Del Gatto, V.
Writing – Original Draft Preparation
;
Papi, G.
Supervision
;
Pontecorvi, A.
Supervision
;
Corsello, S. M.
Writing – Review & Editing
2020

Abstract

Introduction: About one third of patients affected with thyroid cancer present with recurrent disease. Unresectability, advanced disease and radioiodine refractoriness are considered poor prognostic factors. Treatment with small molecules inhibiting molecular signaling can be considered for patients with progressive disease, when other therapeutic strategies cannot be applied. Lenvatinib is a tyrosine kinase inhibitor targeting multiple molecular factors involved in angiogenesis and tumor progression. Preclinical studies have demonstrated the utility of lenvatinib as a targeted therapy for different tumors, including both differentiated and anaplastic thyroid cancer. Areas covered: The authors provide an overview of the preclinical development of lenvatinib in the treatment of thyroid cancer and review its clinical application. They also provide their expert opinion on its development. Expert opinion: Preclinical studies have helped in the understanding of the mechanisms of thyroid carcinogenesis and in the development of a targeted therapy. These findings have represented the rationale for the use of lenvatinib in clinical trials, which have confirmed its utility but yet failed to prove a clear benefit in overall survival. The decision to start a systemic treatment with lenvatinib must be personalized for each patient evaluating the risk/benefits ratio. Treatment emergent adverse events must be considered and reasonably managed by a multidisciplinary approach.
Inglese
Paragliola, R. M., Corsello, A., Del Gatto, V., Papi, G., Pontecorvi, A., Corsello, S. M., Lenvatinib for thyroid cancer treatment: discovery, pre-clinical development and clinical application, <<EXPERT OPINION ON DRUG DISCOVERY>>, 2020; 15 (1): 11-26. [doi:10.1080/17460441.2020.1674280] [http://hdl.handle.net/10807/153190]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/153190
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 8
social impact